HUP0000214A2 - Alfa-szubsztituált benzolszulfonamido-hidroxámsavak, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények - Google Patents

Alfa-szubsztituált benzolszulfonamido-hidroxámsavak, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0000214A2
HUP0000214A2 HU0000214A HUP0000214A HUP0000214A2 HU P0000214 A2 HUP0000214 A2 HU P0000214A2 HU 0000214 A HU0000214 A HU 0000214A HU P0000214 A HUP0000214 A HU P0000214A HU P0000214 A2 HUP0000214 A2 HU P0000214A2
Authority
HU
Hungary
Prior art keywords
alkyl
compounds
benzenesulphonamido
alpha
substituted
Prior art date
Application number
HU0000214A
Other languages
English (en)
Inventor
David Thomas Parker
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0000214A2 publication Critical patent/HUP0000214A2/hu
Publication of HUP0000214A3 publication Critical patent/HUP0000214A3/hu
Publication of HU226123B1 publication Critical patent/HU226123B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány tárgyát (I) általánős képletű vegyületek, gyógyászatilagelfőgadható prődrűgszármazékaik és sóik, valamint az előállításűkraszőlgáló eljárás és az ezeket tartalmazó gyógyszerkészítményekképezik. Az (I) általánős képletben Ar karbő- vagy heterőciklűsősaril- vagy biarilcsőpőrt; Rl alkil-, ciklőalkil-, aralkil-, alkőxi-alkil-, karbő vagy heterőciklűsős aril-, ciklőalkil-alkil- vagyhalőgénezett alkilcsőpőrt, R2 hidrőgénatőm vagy alkilcsőpőrt; R3 és R4jelentése egymástól függetlenül hidrőgénatőm, alkil-, alkőxicsőpőrt,halőgénatőm, hidrőxi-, acil-őxi-, alkőxi-alkőxi-, triflűőr-metil- vagycianőcsőpőrt; vagy együttesen egy két szőmszédős szénatőmhőzkapcsőlódó alkilén-diőxi-csőpőrtőt képeznek; és n 1-5. Az (I)általánős képletű vegyületek és az azőkat tartalmazógyógyszerkészítmények, mint a TNF-a-kőnvertáz és a matrixlebőntómetallőprőteinázők inhibitőrai, gyűlladásgátló szerként példáűl azősteőarthritis vagy reűmatőid arthritis kezelésére, tővábbátűmőrellenes szerként a metasztázis, prőgresszió és inváziókezelésére, és megelőzésére használhatók. ŕ
HU0000214A 1995-12-15 1996-12-03 Alpha-substituted benzenesulphonamido hydroxamic acids, process for their preparation and pharmaceutical compositions containing them HU226123B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US866195P 1995-12-15 1995-12-15
PCT/EP1996/005362 WO1997022587A1 (en) 1995-12-15 1996-12-03 Alpha-substituted arylsulphonamido hydroxamic acids as tnf-alpha and matrix metalloproteinase inhibitors

Publications (3)

Publication Number Publication Date
HUP0000214A2 true HUP0000214A2 (hu) 2000-09-28
HUP0000214A3 HUP0000214A3 (en) 2000-10-30
HU226123B1 HU226123B1 (en) 2008-04-28

Family

ID=21732933

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000214A HU226123B1 (en) 1995-12-15 1996-12-03 Alpha-substituted benzenesulphonamido hydroxamic acids, process for their preparation and pharmaceutical compositions containing them

Country Status (27)

Country Link
US (1) US5770624A (hu)
EP (1) EP0873312B1 (hu)
JP (1) JP4112004B2 (hu)
KR (1) KR100452941B1 (hu)
CN (1) CN1173948C (hu)
AR (1) AR005068A1 (hu)
AT (1) ATE219058T1 (hu)
AU (1) AU709489B2 (hu)
BR (1) BR9612136B1 (hu)
CZ (1) CZ292431B6 (hu)
DE (1) DE69621830T2 (hu)
DK (1) DK0873312T3 (hu)
EA (1) EA002019B1 (hu)
ES (1) ES2178724T3 (hu)
HK (1) HK1011536A1 (hu)
HU (1) HU226123B1 (hu)
IL (1) IL124524A (hu)
MX (1) MX9804793A (hu)
NO (1) NO311643B1 (hu)
NZ (1) NZ324287A (hu)
PL (1) PL187136B1 (hu)
PT (1) PT873312E (hu)
SK (1) SK78998A3 (hu)
TR (1) TR199801105T2 (hu)
TW (1) TW453995B (hu)
WO (1) WO1997022587A1 (hu)
ZA (1) ZA9610532B (hu)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
DE69633947T2 (de) * 1995-12-08 2005-12-01 Agouron Pharmaceuticals, Inc., San Diego Zwischenprodukte zur Herstellung von Metallproteinasehemmern
US5962481A (en) 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5977408A (en) * 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6228869B1 (en) 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
IL127496A0 (en) * 1997-12-19 1999-10-28 Pfizer Prod Inc The use of MMP inhibitors for the treatment of ocular angiogenesis
US6492394B1 (en) * 1998-12-22 2002-12-10 Syntex (U.S.A.) Llc Sulfonamide hydroxamates
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6225311B1 (en) * 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
GB9918684D0 (en) * 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB9922825D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
US6531128B1 (en) 2000-02-08 2003-03-11 Pharmacia Corporation Methods for treating glaucoma
WO2001058469A1 (en) * 2000-02-08 2001-08-16 Wax Martin B Methods for treating glaucoma
US6465508B1 (en) 2000-02-25 2002-10-15 Wyeth Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors
CN1418210A (zh) * 2000-03-21 2003-05-14 宝洁公司 含有碳环侧链的n－取代金属蛋白酶抑制剂
PL365444A1 (en) 2000-03-21 2005-01-10 The Procter & Gamble Company Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
EP1265887A2 (en) * 2000-03-21 2002-12-18 The Procter & Gamble Company Carbocyclic side chain containing metalloprotease inhibitors
AU2001245862A1 (en) 2000-03-21 2001-10-03 The Procter & Gamble Company Difluorobutyric acid metalloprotease inhibitors
CA2464727A1 (en) 2001-11-01 2003-05-08 Wyeth Holdings Corporation Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
PE20030701A1 (es) * 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
GB0208176D0 (en) 2002-04-09 2002-05-22 Novartis Ag Organic compounds
AU2003253346A1 (en) * 2002-07-29 2004-02-23 Novartis Ag Use or arylsulfonamido-substituted hydroxamid acid matrix metalloproteinase inhibitors for the treatment or prevention of toxemia
WO2004056353A2 (en) * 2002-12-20 2004-07-08 Novartis Ag Device and method for delivering mmp inhibitors
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
JP2006519216A (ja) 2003-02-10 2006-08-24 ジーイー・ヘルスケア・リミテッド Ｍｍｐ阻害活性を有する画像診断剤
CA2515534A1 (en) * 2003-02-11 2004-08-26 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and tace-inhibitors
US20100226922A1 (en) * 2006-06-08 2010-09-09 Dorothea Maetzel Specific protease inhibitors and their use in cancer therapy
FR2947270B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
US20140275108A1 (en) 2013-03-15 2014-09-18 Galderma Research & Development Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
EP3199534B1 (en) 2016-02-01 2018-09-05 Galderma Research & Development Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
ATE182581T1 (de) * 1994-06-22 1999-08-15 British Biotech Pharm Metalloproteinase-inhibitoren
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives

Also Published As

Publication number Publication date
NO982579L (no) 1998-06-05
IL124524A0 (en) 1998-12-06
BR9612136A (pt) 1999-07-13
PT873312E (pt) 2002-11-29
AU709489B2 (en) 1999-08-26
HK1011536A1 (en) 1999-07-16
NZ324287A (en) 1999-10-28
CN1204320A (zh) 1999-01-06
ES2178724T3 (es) 2003-01-01
ATE219058T1 (de) 2002-06-15
PL187136B1 (pl) 2004-05-31
TW453995B (en) 2001-09-11
HUP0000214A3 (en) 2000-10-30
NO982579D0 (no) 1998-06-05
EP0873312A1 (en) 1998-10-28
EP0873312B1 (en) 2002-06-12
HU226123B1 (en) 2008-04-28
ZA9610532B (en) 1997-10-24
PL327450A1 (en) 1998-12-07
JP2000502088A (ja) 2000-02-22
DE69621830T2 (de) 2003-01-09
BR9612136B1 (pt) 2010-11-30
IL124524A (en) 2002-12-01
DK0873312T3 (da) 2002-10-07
KR20000064373A (ko) 2000-11-06
NO311643B1 (no) 2001-12-27
DE69621830D1 (en) 2002-07-18
US5770624A (en) 1998-06-23
MX9804793A (es) 1998-10-31
CZ292431B6 (cs) 2003-09-17
EA199800529A1 (ru) 1999-02-25
AU1140697A (en) 1997-07-14
SK78998A3 (en) 1999-02-11
TR199801105T2 (xx) 1998-08-21
JP4112004B2 (ja) 2008-07-02
EA002019B1 (ru) 2001-12-24
CZ185498A3 (cs) 1998-09-16
AR005068A1 (es) 1999-04-07
KR100452941B1 (ko) 2004-12-31
WO1997022587A1 (en) 1997-06-26
CN1173948C (zh) 2004-11-03

Similar Documents

Publication Publication Date Title
HUP0000214A2 (hu) Alfa-szubsztituált benzolszulfonamido-hidroxámsavak, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
HUP9800462A2 (hu) Aril-szulfonil-amino-hidroxámsav-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
HUP0001285A2 (hu) Proteáz inhibitor hatású pirrolidinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
DK0639186T3 (da) Taxolderivater
HUP9700811A2 (hu) Kondenzált vázas tetrahidropiridin-N-hidroxi-karboxamid-származékok, ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására
HUP0003309A2 (hu) Imidazolilcsoportot tartalmazó gyűrűs acetálok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
HUP0104867A2 (hu) Gyulladásos betegségek kezelésére használható heterociklusos vegyületek, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
FI864527A (fi) Tricyklofoereningar, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska blandning.
DE69204662T2 (de) Poly-4-aminopyrrole-2-carboxamide derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
HUP9802408A2 (hu) Naftil- és dihidronaftilszármazékok, és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
HUP9701588A2 (hu) Új flavonszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HUP9801766A2 (hu) 6-Karboxamido-dihidropirán-származékok, eljárás előállításukra és azokat tartalmazó gyógyszerkészítmények
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
HUP9701660A2 (hu) 10,13,15-trioxa-triciklo[9.2.1.1. 9.6]pentadekanon-származékok, eljárás ezek előállítására, és az e vegyületeket tartalmazó gyógyászati készítmények
RU94027686A (ru) Производные ксантина, способ их получения и содержащая их фармацевтическая композиция
ES8600202A1 (es) Procedimiento de preparacion de nuevos derivados dietilaminoalcoxibenzoles y de sus sales de adicion acidas y amonicas cuaternarias
HUP9900911A1 (hu) Gyógyászatilag hatásos zsírsavszármazékok, eljárás ezek előállítására és ezeket tartalmazó gyógyászati készítmények
FI824336L (fi) Fenolestrar
HUP9901212A2 (hu) N,N-dialkil-N-[2-(3-alkoxi-fenoxi)-etil]-amin-származékok, az ezeket tartalmazó gyógyszerkészítmények és helyi érzéstelenítőkként való alkalmazásuk
YU5896A (sh) Primena amida fenilcikloheksilkarbonske kiseline, pojedinačni amidi fenilcikloheksilkarbonske kiseline, postupak za njihovu izradu kao i lekovi koji ih sadrže
HUP9800146A2 (hu) Thalidomidszármazékok, eljárás előállításukra és felhasználásuk
HUP9800422A1 (hu) 2-Amino-indán-származékok, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyászati készítmények
ATE56713T1 (de) 1,2,3,4,4a,9b-hexahydro-4aaminoalkyldibenzofurane, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ES8101074A1 (es) Procedimiento para la preparacion de derivados de xantina
HUP9801327A2 (hu) Benzotiofénszármazékok felhasználása a petefészekrák gátlására alkalmas gyógyszerkészítmények előállítására

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees